Document is current
Any future updates will be listed below
-
Authors
Li, Jing https://orcid.org/0000-0003-1647-4852
Velaga, Ravi
Takano, Yuko https://orcid.org/0000-0002-3753-7683
Masuda, Norikazu https://orcid.org/0000-0002-7302-0278
- License Information
-
More Information
Article History
Received: 12 May 2025
Accepted: 29 October 2025
First Online: 6 November 2025
Declarations
:
: JL, RV have no competing interests to declare. YT: Honoraria (e.g. lecture fees) from AstraZeneca, Chugai, Daiichi Sankyo, Eli-Lilly, and Pfizer. Research funding to institution from Eli-Lilly. NM: Honoraria (e.g. lecture fees) from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli-Lilly, Gilead Sciences, MSD, and Pfizer. Research funding to institution from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli-Lilly, Gilead Sciences, MSD, Novartis, Ono-Pharma, and Pfizer. Board of directors: Japanese Breast Cancer Society (JBCS; 2021–2024), Japan Society of Clinical Oncology (JSCO; 2023-), Japan Association of Breast Cancer Screening (JABCS; 2024-), and Japan Breast Cancer Research Group Association (JBCRG).
